Stock Events

Stock Events

Prelude Therapeutics 

$1.96
0
+$0.05+2.62% Today

Statistics

Day High
2.11
Day Low
1.96
52W High
-
52W Low
-
Volume
73
Avg. Volume
-
Mkt Cap
82.91M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MarExpected
Q3 2025
Next
-0.37
-0.26
-0.14
-0.03
Expected EPS
-0.03
Actual EPS
N/A

Financials

-1,816.76%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
14MRevenue
-254.35MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PRLD.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a technology that can be applied to cancer treatment, making it a competitor in the oncology space.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a broad oncology portfolio, competing across multiple areas including those targeted by Prelude.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a strong presence in oncology and cell therapy, areas where Prelude is aiming to make advancements.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb has a diverse oncology pipeline that includes cell therapy and biologics, competing with Prelude's cancer research efforts.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has a broad portfolio in cancer therapeutics, directly competing with Prelude's focus on innovative cancer treatments.
Merck
MRK
Mkt Cap214.76B
Merck is known for its cancer drug Keytruda among others, making it a strong competitor in the oncology market.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a wide range of cancer treatments and is heavily invested in oncology research, competing with Prelude's therapeutic developments.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is involved in developing monoclonal antibodies for cancer, directly competing with Prelude's approach to cancer therapy.

About

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Show more...
CEO
Dr. Krishna Vaddi D.V.M., Ph.D.
Employees
131
Country
US
ISIN
US74065P1012

Listings

XNAS
US
PRLD
BOATS
BOATS
PRLD.BOATS

0 Comments

Share your thoughts

FAQ

What is Prelude Therapeutics stock price today?▼
The current price of PRLD.BOATS is $1.96 USD — it has increased by +2.62% in the past 24 hours. Watch Prelude Therapeutics stock price performance more closely on the chart.
What is Prelude Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Prelude Therapeutics stocks are traded under the ticker PRLD.BOATS.
What is Prelude Therapeutics market cap?▼
Today Prelude Therapeutics has the market capitalization of 82.91M
When is the next Prelude Therapeutics earnings date?▼
Prelude Therapeutics is going to release the next earnings report on March 18, 2026.
What were Prelude Therapeutics earnings last quarter?▼
PRLD.BOATS earnings for the last quarter are -0.26 USD per share, whereas the estimation was -0.37 USD resulting in a +29.73% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Prelude Therapeutics revenue for the last year?▼
Prelude Therapeutics revenue for the last year amounts to 14M USD.
What is Prelude Therapeutics net income for the last year?▼
PRLD.BOATS net income for the last year is -254.35M USD.
How many employees does Prelude Therapeutics have?▼
As of February 03, 2026, the company has 131 employees.
In which sector is Prelude Therapeutics located?▼
Prelude Therapeutics operates in the Health Care sector.
When did Prelude Therapeutics complete a stock split?▼
Prelude Therapeutics has not had any recent stock splits.
Where is Prelude Therapeutics headquartered?▼
Prelude Therapeutics is headquartered in Wilmington, US.